Travere Therapeutics (NASDAQ:TVTX) Director Gary Lyons Sells 8,000 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Gary Lyons sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total transaction of $328,560.00. Following the completion of the sale, the director directly owned 57,500 shares of the company’s stock, valued at $2,361,525. This represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Down 3.4%

Travere Therapeutics stock opened at $39.54 on Friday. Travere Therapeutics, Inc. has a one year low of $13.88 and a one year high of $43.31. The company’s fifty day moving average price is $29.77 and its two-hundred day moving average price is $31.42. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70. The company has a market capitalization of $3.65 billion, a price-to-earnings ratio of -131.80 and a beta of 0.86.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in Travere Therapeutics in the second quarter valued at about $33,000. First Horizon Corp bought a new position in Travere Therapeutics during the third quarter worth about $36,000. State of Wyoming acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $37,000. Torren Management LLC acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $38,000. Finally, Comerica Bank grew its stake in shares of Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after purchasing an additional 492 shares during the period.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in FSGS, materially expanding Travere’s rare‑kidney franchise and adding an estimated ~30,000 U.S. patients to the addressable market — the core reason for the earlier, large share price gain. Filspari approval article
• Positive Sentiment: Market reaction and analyst upgrades lifted sentiment and targets (examples: Canaccord, Guggenheim, Piper Sandler, HC Wainwright), reinforcing a re‑rating narrative and supporting higher medium‑term revenue expectations for Filspari. Guggenheim note
• Neutral Sentiment: Trading activity is elevated and options volumes spiked around the approval — this amplifies short‑term moves (both up and down) and suggests greater volatility while the market digests label details and early commercialization assumptions. Options activity report
• Neutral Sentiment: Company commentary and coverage (conference/transcript writeups, health press) are clarifying the label and launch plans, but concrete revenue/volume reads are not yet available — useful for modeling but not definitive. Company discussion
• Negative Sentiment: Multiple insiders (CEO, directors, CFO, other executives) sold material blocks of shares over the last two trading days — most sales were executed under pre‑arranged Rule 10b5‑1 plans or to cover taxes related to vesting, but the scale of selling can fuel near‑term downward pressure and signal profit‑taking after the approval‑driven rally. Example SEC filing for CEO sale. CEO Form 4
• Negative Sentiment: Some analysts warn that estimate‑revision trends and elevated expectations could limit near‑term upside — the stock may consolidate or pull back as investors re‑rate forward revenue assumptions. Zacks caution

Analyst Upgrades and Downgrades

TVTX has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday. Citigroup raised their target price on shares of Travere Therapeutics from $48.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler raised shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price for the company in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Finally, Wall Street Zen downgraded Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.